139 related articles for article (PubMed ID: 8864963)
21. Structural elucidation of the N- and O-glycans of human apolipoprotein(a): role of o-glycans in conferring protease resistance.
Garner B; Merry AH; Royle L; Harvey DJ; Rudd PM; Thillet J
J Biol Chem; 2001 Jun; 276(25):22200-8. PubMed ID: 11294842
[TBL] [Abstract][Full Text] [Related]
22. Oxidation of apolipoprotein(a) inhibits kringle-associated lysine binding: the loss of intrinsic protein fluorescence suggests a role for tryptophan residues in the lysine binding site.
Hermann A; Laws WR; Harpel PC
Protein Sci; 1997 Nov; 6(11):2324-35. PubMed ID: 9385634
[TBL] [Abstract][Full Text] [Related]
23. In vitro proteolysis of human plasma low density lipoproteins by an elastase released from human blood polymorphonuclear cells.
Polacek D; Byrne RE; Fless GM; Scanu AM
J Biol Chem; 1986 Feb; 261(5):2057-63. PubMed ID: 3632977
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in human apolipoprotein(a) kringle IV-10 and coronary artery disease: relationship to allele size, plasma lipoprotein(a) concentration, and lysine binding site activity.
Simó JM; Joven J; Vilella E; Ribas M; Figuera L; Virgos C; Sundaram IM; Hoover-Plow J
J Mol Med (Berl); 2001 Jun; 79(5-6):294-9. PubMed ID: 11485023
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains.
Tsurupa G; Ho-Tin-Noé B; Anglés-Cano E; Medved L
J Biol Chem; 2003 Sep; 278(39):37154-9. PubMed ID: 12853452
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments.
Rouy D; Koschinsky ML; Fleury V; Chapman J; Anglés-Cano E
Biochemistry; 1992 Jul; 31(27):6333-9. PubMed ID: 1627572
[TBL] [Abstract][Full Text] [Related]
27. The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions.
D'Angelo A; Geroldi D; Hancock MA; Valtulina V; Cornaglia AI; Spencer CA; Emanuele E; Calligaro A; Koschinsky ML; Speziale P; Visai L
Biochim Biophys Acta; 2005 Feb; 1687(1-3):1-10. PubMed ID: 15708348
[TBL] [Abstract][Full Text] [Related]
28. Metabolism of Lp(a): assembly and excretion.
Kostner GM; Wo X; Frank S; Kostner K; Zimmermann R; Steyrer E
Clin Genet; 1997 Nov; 52(5):347-54. PubMed ID: 9520125
[TBL] [Abstract][Full Text] [Related]
29. Lys and fibrinogen binding of wild-type (Trp72) and mutant (Arg72) human apo(a) kringle IV-10 expressed in E coli and CHO cells.
Klezovitch O; Scanu AM
Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):392-8. PubMed ID: 8630665
[TBL] [Abstract][Full Text] [Related]
30. Molecular cloning of the cDNA encoding the carboxy-terminal domain of chimpanzee apolipoprotein(a): an Asp57 --> Asn mutation in kringle IV-10 is associated with poor fibrin binding.
Chenivesse X; Huby T; Wickins J; Chapman J; Thillet J
Biochemistry; 1998 May; 37(20):7213-23. PubMed ID: 9585533
[TBL] [Abstract][Full Text] [Related]
31. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody.
Kang C; Dominguez M; Loyau S; Miyata T; Durlach V; Anglés-Cano E
Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1232-8. PubMed ID: 12117743
[TBL] [Abstract][Full Text] [Related]
32. The Kringle V-protease domain is a fibrinogen binding region within Apo(a).
Xue S; Madison EL; Miles LA
Thromb Haemost; 2001 Nov; 86(5):1229-37. PubMed ID: 11816712
[TBL] [Abstract][Full Text] [Related]
33. Isolation and characterization of two sub-species of Lp(a), one containing apo E and one free of apo E.
Bard JM; Delattre-Lestavel S; Clavey V; Pont P; Derudas B; Parra HJ; Fruchart JC
Biochim Biophys Acta; 1992 Jul; 1127(2):124-30. PubMed ID: 1322706
[TBL] [Abstract][Full Text] [Related]
34. Proteolytic degradation of low-density lipoprotein by lipoprotein(a) and by recombinant apo(a).
Pursiainen M; Jauhiainen M; Kovanen PT; Ehnholm C
Chem Phys Lipids; 1994 Jan; 67-68():25-33. PubMed ID: 8187221
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a).
Gabel BR; Koschinsky MI
Biochemistry; 1995 Dec; 34(48):15777-84. PubMed ID: 7495809
[TBL] [Abstract][Full Text] [Related]
36. The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation or degradation.
Seifert PS; Roth I; Zioncheck TF
Atherosclerosis; 1992 Apr; 93(3):209-16. PubMed ID: 1534227
[TBL] [Abstract][Full Text] [Related]
37. Oxidative events cause degradation of apoB-100 but not of apo[a] and facilitate enzymatic cleavage of both proteins.
Edelstein C; Nakajima K; Pfaffinger D; Scanu AM
J Lipid Res; 2001 Oct; 42(10):1664-70. PubMed ID: 11590223
[TBL] [Abstract][Full Text] [Related]
38. Electron-microscopic and hydrodynamic characterization of recombinant apolipoprotein (a) and its association with LDL.
Phillips ML; Lembertas AV; Schumaker VN; Lawn RM; Shire SJ; Zioncheck TF
Chem Phys Lipids; 1994 Jan; 67-68():91-7. PubMed ID: 8187249
[TBL] [Abstract][Full Text] [Related]
39. Neutrophils stimulated by apolipoprotein(a) generate fragments that are stronger inhibitors of plasmin formation than apo(a).
Lamanuzzi LB; Mtairag el M; Pepe G; Anglés-Cano E
Thromb Haemost; 2004 Nov; 92(5):1066-75. PubMed ID: 15543335
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
Xue S; Green MA; LoGrasso PV; Boettcher BR; Madison EL; Curtiss LK; Miles LA
Thromb Haemost; 1999 Mar; 81(3):428-35. PubMed ID: 10102473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
